Home
/
Magnesium

Why Your Heart Needs Magnesium

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 31, 2026
Last updated
May 30, 2026
Quick answer:

Magnesium regulates the heart's electrical system by acting as a physiological calcium antagonist and controlling the sodium-potassium ATPase pump. Only 1% of total body magnesium circulates in serum, so standard blood tests routinely miss deficiency — yet low magnesium raises the risk of atrial fibrillation, ventricular tachycardia, and torsades de pointes.

Read more →
Table of contents

You've felt it before: that sudden flutter in your chest, the sensation that your heart just skipped a beat or started racing for no clear reason. Most people dismiss it as stress or too much coffee. But for many, those heart palpitations trace back to something far more fundamental: a mineral deficiency that standard blood work routinely misses.

Heart palpitations often signal disrupted cardiac electrical activity, and magnesium deficiency is one of the most common yet overlooked causes. Superpower's baseline panel includes RBC magnesium, the marker that serum testing misses, alongside the full cardiovascular and electrolyte context your heart depends on.

Key Takeaways

  • Magnesium regulates cardiac rhythm by controlling calcium channels and electrical impulse timing.
  • Serum magnesium misses most deficiencies because only 1% of total body magnesium circulates in blood.
  • Low magnesium increases risk of atrial fibrillation, ventricular arrhythmias, and sudden cardiac events.
  • Magnesium acts as a natural calcium channel blocker, preventing excessive cardiac muscle contraction.
  • Deficiency disrupts potassium and sodium balance, compounding electrical instability in the heart.
  • RBC magnesium testing reveals intracellular stores that determine true cardiac magnesium status.
  • Magnesium supplementation reduces arrhythmia risk most effectively in those with documented deficiency.

What Magnesium Does in the Heart, and Why Deficiency Disrupts Rhythm

Magnesium is the fourth most abundant cation in the body and the second most abundant intracellular cation after potassium. In the heart, it functions as a critical regulator of electrical excitability, ion channel activity, and myocardial contraction. Unlike calcium, which drives muscle contraction and electrical depolarization, magnesium acts as a physiological calcium antagonist, modulating the entry of calcium into cardiac cells and preventing excessive excitation.

The heart's electrical system depends on the coordinated movement of sodium, potassium, calcium, and magnesium across cell membranes. Magnesium stabilizes this system by regulating ion channels, particularly the L-type calcium channels that control the plateau phase of the cardiac action potential. When magnesium levels drop, calcium channels become hyperactive, allowing excessive calcium influx. This disrupts the normal rhythm of depolarization and repolarization, creating conditions for arrhythmias ranging from benign premature ventricular contractions to life-threatening ventricular tachycardia and torsades de pointes.

Regulation of cellular ion pumps

Magnesium regulates the sodium-potassium ATPase pump, which maintains the electrochemical gradient essential for cardiac excitability. Deficiency impairs this pump, leading to intracellular potassium depletion and sodium accumulation. The result is a destabilized resting membrane potential and increased susceptibility to abnormal electrical impulses. This is why magnesium deficiency often coexists with hypokalemia, and why correcting potassium alone without addressing magnesium rarely resolves the arrhythmia.

Why standard testing misses deficiency

The problem with detecting magnesium deficiency is that serum magnesium, the standard test, reflects only extracellular stores, which represent less than 1% of total body magnesium. The majority resides intracellularly, particularly in bone, muscle, and soft tissue. A person can have normal serum magnesium while being functionally deficient at the cellular level, where it matters most for cardiac function. This is why RBC magnesium is a more accurate marker: it reflects intracellular stores and correlates better with tissue magnesium status.

The Clinical Evidence Linking Magnesium Deficiency to Cardiac Arrhythmias

Multiple studies have documented the association between low magnesium and increased arrhythmia risk. A 2022 systematic review in BMC Cardiovascular Disorders found that magnesium supplementation significantly reduced the incidence of postoperative atrial fibrillation in cardiac surgery patients, with an odds ratio of 0.42 compared to placebo. The effect was most pronounced when magnesium was given prophylactically rather than as a rescue intervention.

In patients with documented hypomagnesemia, the link to ventricular arrhythmias is particularly strong. Low serum magnesium has been associated with a higher incidence of premature ventricular contractions, ventricular tachycardia, and torsades de pointes, especially in the setting of other electrolyte disturbances or QT-prolonging medications (2018 non-rct observational study). Magnesium sulfate is the first-line treatment for torsades de pointes, even in patients with normal serum magnesium, because it stabilizes the cardiac membrane and shortens the QT interval through mechanisms that extend beyond simple repletion.

The evidence for magnesium supplementation in preventing arrhythmias in the general population is more nuanced. A 2019 study in Circulation: Genomics and Precision Medicine examined serum magnesium and calcium levels in relation to atrial fibrillation risk. Higher magnesium levels were associated with a lower risk of atrial fibrillation, but the relationship was nonlinear, and supplementation trials in individuals with normal baseline magnesium have not consistently shown benefit (2025 meta-analysis). This suggests that magnesium's antiarrhythmic effect is most relevant in those who are deficient or at the lower end of the normal range.

Population-specific evidence

Certain populations are at higher risk for magnesium deficiency and its cardiac consequences:

  • Patients on diuretics, particularly loop and thiazide diuretics, lose magnesium through renal wasting.
  • Proton pump inhibitors impair magnesium absorption in the gut.
  • Diabetics experience increased urinary magnesium loss due to osmotic diuresis.
  • Older adults have reduced intestinal absorption and higher rates of medication use that depletes magnesium.

How Magnesium Regulates Cardiac Electrical Activity and Vascular Tone

Magnesium's antiarrhythmic properties stem from its role as a natural calcium antagonist. Calcium is the primary driver of cardiac muscle contraction and electrical excitation. When calcium enters cardiac cells through voltage-gated L-type calcium channels, it triggers the release of more calcium from intracellular stores, initiating contraction. Magnesium competes with calcium for binding sites on these channels, reducing calcium influx and preventing excessive depolarization.

This mechanism is particularly important during the plateau phase of the cardiac action potential, when calcium channels remain open and calcium continues to enter the cell. Magnesium shortens this plateau phase, reducing the duration of the action potential and the refractory period. This helps prevent early afterdepolarizations, which are abnormal electrical impulses that can trigger arrhythmias like torsades de pointes.

Regulation of potassium channels

Magnesium also modulates potassium channels, which are responsible for repolarization (the process by which the cardiac cell returns to its resting state after depolarization). Magnesium deficiency impairs potassium channel function, prolonging repolarization and increasing the risk of delayed afterdepolarizations. This creates a substrate for reentrant arrhythmias, where electrical impulses circulate abnormally through the heart tissue.

Effects on the autonomic nervous system

Beyond its direct effects on ion channels, magnesium influences the autonomic nervous system, which regulates heart rate and rhythm. Magnesium deficiency increases sympathetic nervous system activity, raising catecholamine levels and heart rate. This heightened sympathetic tone increases the likelihood of arrhythmias, particularly in individuals with underlying structural heart disease or ischemia. Magnesium supplementation has been shown to reduce sympathetic activity and improve heart rate variability, a marker of autonomic balance and cardiovascular health (2018 non-rct observational study).

Vascular smooth muscle and blood pressure

Magnesium relaxes vascular smooth muscle by inhibiting calcium entry into smooth muscle cells, leading to vasodilation and reduced blood pressure. Chronic magnesium deficiency contributes to endothelial dysfunction, increased vascular resistance, and hypertension, all of which increase the workload on the heart and the risk of arrhythmias. The relationship between magnesium and blood pressure is dose-dependent, with meta-analyses showing that supplementation at doses of 300 to 400 mg per day modestly reduces systolic and diastolic blood pressure in hypertensive individuals (2016 meta-analysis).

Magnesium Forms, Dosing, and Timing for Cardiovascular Support

Not all magnesium supplements are absorbed equally. Magnesium bound to organic acids, such as magnesium citrate, glycinate, and malate, has higher bioavailability than inorganic salts like magnesium oxide. Magnesium oxide is poorly absorbed, with bioavailability around 4%, and is more commonly used as a laxative than a cardiovascular supplement. For heart health, magnesium glycinate is often preferred because it is well-absorbed and less likely to cause gastrointestinal side effects.

Dose

The recommended dietary allowance for magnesium is 400 to 420 mg per day for men and 310 to 320 mg per day for women (2021 literature review). These values are set to prevent deficiency, not to optimize cardiovascular function. Clinical trials examining magnesium's effects on arrhythmias and blood pressure have used doses ranging from 300 to 600 mg per day, typically divided into two or three doses to improve absorption and minimize gastrointestinal upset (2016 meta-analysis). The upper tolerable limit for supplemental magnesium is 350 mg per day from supplements alone, though this does not include magnesium from food (2023 meta-analysis). Doses above this threshold increase the risk of diarrhea, the most common side effect of magnesium supplementation.

Timing

Magnesium is best absorbed when taken with food, as gastric acid enhances solubility. Taking magnesium in the evening may also support sleep, as magnesium promotes relaxation through its effects on GABA receptors and the hypothalamic-pituitary-adrenal axis. For individuals taking medications that interact with magnesium, such as bisphosphonates, tetracycline antibiotics, or certain thyroid medications, spacing magnesium supplementation at least two hours apart from these drugs is necessary to avoid reduced absorption of either compound.

Interactions with other electrolytes

Magnesium does not act in isolation. It works synergistically with potassium, and deficiency in one often coexists with deficiency in the other. Correcting hypokalemia without addressing magnesium is often ineffective because magnesium is required for the sodium-potassium ATPase pump to function properly. Similarly, magnesium and calcium have an inverse relationship: high calcium intake can impair magnesium absorption, and excessive calcium supplementation without adequate magnesium may worsen cardiovascular outcomes. The optimal ratio of calcium to magnesium intake is debated, but a 2:1 ratio is commonly cited.

Who Benefits Most from Magnesium Supplementation, and Who Should Be Cautious

Magnesium supplementation is most beneficial for individuals with documented deficiency or those at high risk of depletion:

  • Patients on diuretics, proton pump inhibitors, or other medications that impair magnesium absorption or increase renal loss.
  • Diabetics, particularly those with poorly controlled blood sugar, who lose magnesium through osmotic diuresis.
  • Older adults, who have reduced intestinal absorption and higher rates of polypharmacy.
  • Individuals with a history of arrhythmias, particularly atrial fibrillation or ventricular ectopy.
  • Athletes and individuals under chronic stress who may have higher magnesium requirements due to increased losses through sweat and the effects of cortisol on renal magnesium handling.

Populations requiring caution

Magnesium supplementation is not without risk. Individuals with chronic kidney disease, particularly those with a glomerular filtration rate below 30 mL/min, are at risk of hypermagnesemia because the kidneys are the primary route of magnesium excretion. Elevated magnesium levels can cause muscle weakness, hypotension, bradycardia, and in severe cases, cardiac arrest. Patients with advanced kidney disease should only take magnesium under medical supervision.

Magnesium can also interact with certain medications. It enhances the effects of calcium channel blockers and may cause excessive hypotension or bradycardia when taken concurrently. It can reduce the absorption of bisphosphonates, tetracycline antibiotics, and levothyroxine. Individuals taking these medications should space magnesium supplementation appropriately or consult with a healthcare provider.

Pregnancy and lactation

Magnesium requirements increase during pregnancy and lactation. Magnesium sulfate is used therapeutically to prevent seizures in preeclampsia and to delay preterm labor. Oral magnesium supplementation is generally considered safe during pregnancy, but doses should not exceed the upper tolerable limit without medical guidance. Pregnant women with a history of arrhythmias or hypertension may benefit from magnesium supplementation, but this should be individualized based on baseline status and clinical context.

Testing Magnesium Status: Why RBC Magnesium Reveals What Serum Misses

Serum magnesium is the most commonly ordered test, but it is a poor indicator of total body magnesium status. Because only 1% of magnesium is extracellular, serum levels can remain normal even when intracellular stores are depleted. This is why individuals with normal serum magnesium can still experience symptoms of deficiency, including heart palpitations, muscle cramps, and fatigue.

RBC magnesium measures the magnesium content inside red blood cells, which correlates more closely with intracellular magnesium stores in other tissues, including the heart. Studies have shown that RBC magnesium is a more sensitive marker of deficiency than serum magnesium, particularly in chronic conditions where depletion occurs gradually (2024 non-rct observational study). However, RBC magnesium is not widely available in standard lab panels, and many clinicians are unfamiliar with its interpretation.

Another option is the magnesium loading test, in which a known dose of intravenous or oral magnesium is administered, and urinary magnesium excretion is measured over 24 hours. Individuals who retain a high percentage of the administered magnesium are considered deficient. This test is more cumbersome and is typically reserved for research settings or cases where deficiency is strongly suspected but not confirmed by other methods.

Interpreting magnesium levels in context

Magnesium status should not be evaluated in isolation. Concurrent measurement of calcium, potassium, and vitamin D provides a more complete picture of electrolyte balance and cardiovascular risk. Low magnesium often coexists with low potassium, and correcting one without the other is ineffective. Vitamin D deficiency impairs magnesium absorption, and magnesium is required for the activation of vitamin D, creating a bidirectional relationship that affects both bone and cardiovascular health.

Inflammatory markers such as high-sensitivity C-reactive protein are also relevant, as chronic inflammation increases magnesium requirements and may contribute to depletion. Ferritin, while primarily a marker of iron stores, is an acute-phase reactant and can be falsely elevated in the presence of inflammation, complicating the interpretation of other nutrient markers.

Getting a Complete Picture of Your Cardiovascular and Electrolyte Status

Magnesium is one piece of a larger cardiovascular puzzle. Arrhythmias and palpitations can result from electrolyte imbalances, thyroid dysfunction, autonomic dysregulation, or structural heart disease. Testing magnesium alone does not provide the full context needed to understand why your heart is misfiring. Superpower's 100+ biomarker panel includes RBC magnesium alongside calcium, potassium, sodium, vitamin D, thyroid hormones, inflammatory markers, and cardiovascular risk factors like apolipoprotein B and lipoprotein(a). This comprehensive approach reveals not just whether you're deficient, but how that deficiency fits into your broader metabolic and cardiovascular health. Whether you're experiencing palpitations, managing hypertension, or optimizing performance, knowing where your magnesium and related markers actually sit gives you a foundation for intervention that guesswork never will.

FAQs

Magnesium stabilizes the cardiac action potential by regulating L-type calcium channels and the sodium-potassium ATPase pump. When magnesium drops, calcium channels become hyperactive, causing excessive calcium influx that disrupts the normal rhythm of depolarization and repolarization. This electrical instability creates conditions for arrhythmias including premature ventricular contractions and torsades de pointes, which are often felt as palpitations or skipped beats.

Serum magnesium reflects only extracellular stores, which represent less than 1% of total body magnesium. This means levels can appear normal even when intracellular stores in the heart, muscle, and bone are depleted. RBC magnesium measures magnesium inside red blood cells, correlating more closely with true intracellular status and providing a more sensitive marker of functional deficiency, particularly in chronic conditions where depletion accumulates gradually.

Four groups face elevated risk: patients on loop or thiazide diuretics, which increase renal magnesium wasting; people taking proton pump inhibitors, which impair gut absorption; diabetics, who lose magnesium through osmotic diuresis; and older adults, who have reduced intestinal absorption and are more likely to take multiple medications that deplete magnesium. Athletes under chronic stress also have higher requirements due to sweat losses and cortisol-driven renal handling.

Magnesium competes with calcium for binding sites on voltage-gated L-type calcium channels, reducing calcium influx into cardiac cells. This shortens the plateau phase of the cardiac action potential, decreases the refractory period, and prevents early afterdepolarizations — abnormal impulses that trigger arrhythmias like torsades de pointes. The mechanism is pharmacologically similar to pharmaceutical calcium channel blockers, but mediated physiologically through intracellular magnesium concentration.

A 2022 systematic review in BMC Cardiovascular Disorders found that magnesium supplementation reduced the incidence of postoperative atrial fibrillation in cardiac surgery patients, with an odds ratio of 0.42 compared to placebo — roughly a 58% relative risk reduction. The protective effect was most pronounced when magnesium was administered prophylactically before surgery rather than as a rescue therapy after arrhythmia onset.

Magnesium is required for the sodium-potassium ATPase pump to function. This pump maintains the electrochemical gradient that keeps cardiac cells electrically stable. When magnesium is deficient, the pump is impaired, causing intracellular potassium to deplete and sodium to accumulate even when potassium is supplemented. Without restoring magnesium, the pump cannot work properly, and hypokalemia recurs or persists regardless of potassium replacement.

References

  1. Lazzerini, P. E., Bertolozzi, I., Finizola, F., Acampa, M., Natale, M., Vanni, F., Fulceri, R., Gamberucci, A., Rossi, M., Giabbani, B., Caselli, M., Lamberti, I., Cevenini, G., Laghi-Pasini, F., & Capecchi, P. L. (2018). Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes. Frontiers in pharmacology, 9, 363. https://doi.org/10.3389/fphar.2018.00363
  2. Ghazizadeh, S., Malektojari, A., Javidfar, Z., Lahuti, S., Shokraei, R., Zeinaee, M., Badele, A., Mirzadeh, R., Ashrafi, M., Afra, F., Hamed Ersi, M., Heydari, M., Ziaei, A., Rezvani, Z., Mah, J., Zeraatkar, D., Abbaszadeh, S., & Pitre, T. (2025). Magnesium for Prevention of New-onset Postoperative Atrial Fibrillation Following Cardiac Surgery: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Heart international, 19(1), 3-11. https://doi.org/10.17925/HI.2025.19.1.6
  3. University of Medicine and Pharmacy “Grigore T. Popa” Iași, România, Matei, D., Luca, C., University of Medicine and Pharmacy “Grigore T. Popa” Iași, România, Andrițoi, D., University of Medicine and Pharmacy “Grigore T. Popa” Iași, România, Sărdaru, D., University of Medicine and Pharmacy “Grigore T. Popa” Iași, România, Corciovă, C., & University of Medicine and Pharmacy “Grigore T. Popa” Iași, România (2018). THE RELATIONSHIP BETWEEN LOWER SERUM MAGNESIUM LEVELS AND HEART RATE VARIABILITY INDICES. Balneo Research Journal, 9(4), 426-432. https://doi.org/10.12680/balneo.2018.226
  4. Zhang, X., Li, Y., Del Gobbo, L. C., Rosanoff, A., Wang, J., Zhang, W., & Song, Y. (2016). Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials. Hypertension (Dallas, Tex. : 1979), 68(2), 324-33. https://doi.org/10.1161/HYPERTENSIONAHA.116.07664
  5. Fiorentini, D., Cappadone, C., Farruggia, G., & Prata, C. (2021). Magnesium: Biochemistry, Nutrition, Detection, and Social Impact of Diseases Linked to Its Deficiency. Nutrients, 13(4). https://doi.org/10.3390/nu13041136
  6. Costello, R., Rosanoff, A., Nielsen, F., & West, C. (2023). Perspective: Call for Re-evaluation of the Tolerable Upper Intake Level for Magnesium Supplementation in Adults. Advances in nutrition (Bethesda, Md.), 14(5), 973-982. https://doi.org/10.1016/j.advnut.2023.06.008
  7. Veldscholte, K., Al Fify, M., Catchpole, A., Talwar, D., Wadsworth, J., Vanhorebeek, I., Casaer, M. P., Van den Berghe, G., Joosten, K. F. M., Gerasimidis, K., & Verbruggen, S. C. A. T. (2024). Plasma and red blood cell concentrations of zinc, copper, selenium and magnesium in the first week of paediatric critical illness. Clinical nutrition (Edinburgh, Scotland), 43(2), 543-551. https://doi.org/10.1016/j.clnu.2024.01.004

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey